

PENGANA HIGH CONVICTION EQUITIES FUND

DESCRIPTION

The Pengana High Conviction Equities Fund (the Fund) invests globally in a concentrated portfolio of up to 20 stocks. The Fund can invest in both small and large cap stocks and is diversified across countries and sectors. We avoid investment in companies that are currently, in our opinion, unnecessarily harmful to people, animals or the environment.


PERFORMANCE TABLE

NET PERFORMANCE FOR PERIODS ENDING 31 Oct 2024¹

	1 MTH	1 YEAR	2 YEARS P.A.	3 YEARS P.A.	5 YEARS P.A.	SINCE INCEPTION P.A.
High Conviction Equities Fund Class A	-3.9%	116.9%	47.7%	19.5%	18.2%	26.6%
MSCI World Total Return Index (net, AUD)	3.8%	29.2%	20.1%	11.3%	13.2%	12.5%
RBA Cash Rate plus 3%	0.6%	7.4%	7.0%	5.9%	4.8%	4.7%

PERFORMANCE CHART

NET PERFORMANCE SINCE INCEPTION²



TOP HOLDINGS (ALPHABETICALLY)

Brazilian Rare Earths Ltd.	Materials
Genetic Signatures Ltd	Health Care
Greatland Gold plc	Materials
IperionX Ltd	Materials
Iperionx Ltd. Sponsored ADR	Materials

SECTOR BREAKDOWN

Consumer Discretionary	1.3%
Health Care	46.9%
Information Technology	0.7%
Materials	44.1%
Options	2.1%
Cash	4.9%

CAPITALISATION BREAKDOWN

Under 5bn USD	93%
Derivatives	2.1%
Cash	4.9%

REGION BREAKDOWN

North America	13.8%
Australia/New Zealand	73.5%
UK	5.7%
Options	2.1%
Cash	4.9%

STATISTICAL DATA

VOLATILITY³ 25%

NUMBER OF STOCKS 16

BETA⁴ 0.63

MAXIMUM DRAW DOWN -32.1%

OCTOBER REPORT

COMMENTARY

The Fund fell 3.9% in October but is up 117% over one year.

- IperionX rose 10% post-\$100m capital raise; EBR Systems gained 27%.
- Opthea increased 14%, and Genetic Signatures rose 7% after investor meetings.
- Oncosil fell 39%, Amplia dropped 11%, and Clarity Pharmaceutical declined 13%.

Titanium technology company **IperionX** rose 10% after completing a \$100m capital raise, which we participated in. Fund manager Regal has since disclosed a 6% holding. We view the strengthening of the balance sheet very positively as it enables the company to accelerate its development plans.

The Fund invested in a new holding, cardiac rhythm management device producer **EBR Systems**, which rose 27%. We expect the company to receive FDA approval in March next year, which will be a significant catalyst.

Ophthalmic drug developer **Opthea** rose 14% on little news.

Molecular diagnostic company **Genetic Signatures** rose 7% after newly appointed CEO Allison Rossiter, formerly head of Roche Australia, met with investors. Quarterly results highlighted advanced preparations for the company's new enteric test launch with a pipeline of 60 customers.

On the negative side, pancreatic radiation therapy developer **Oncosil** fell 39% after conducting a capital raising, which the fund participated in. The company did however have excellent news from the German government, which agreed to fund a large randomized phase 3 clinical study. Not only can the company sell the device into the study, but it also allows the company to negotiate insurance reimbursement with a large number of hospitals.

Pancreatic drug developer **Amplia** fell 11% after also announcing a capital raising, which we supported. Our experience has been it takes several months for the market to digest the offerings before share price recovery occurs.

Clarity Pharmaceutical fell 13% on little news.

FEATURES

APIR CODE	Class A: HHA0020AU Class B: PCL9196AU
REDEMPTION PRICE	Class A: A\$ 3.952 Class B: A\$ 1.6746
FEES *	Management Fee: 1.80% p.a. (Class A) 1.25% p.a. (Class B) Performance Fee: 15.38% (Class A) 20% (Class B)
MINIMUM INITIAL INVESTMENT	A\$10,000
FUM AT MONTH END	A\$ 82.74m
STRATEGY INCEPTION DATE	11 December 2014
BENCHMARK	RBA Cash Rate + 3%

FUND MANAGERS



James McDonald
Portfolio Manager



Jeremy Bendeich
Portfolio Manager

1. Net performance figures are shown are those of Class A Units, after all fees and expenses and assume reinvestment of distributions. No allowance has been made for buy/sell spreads. Please refer to the PDS for information regarding risks. Past performance is not a reliable indicator of future performance, the value of investments can go up and down.

2. Inception 11 December 2014.

3. Annualised standard deviation since inception.

4. Relative to MSCI World. Using daily returns.

* For further information regarding fees please see the PDS available on our website.

PENGANA HIGH CONVICTION EQUITIES FUND

PENGANA CAPITAL LIMITED

ABN 30 103 800 568

AFSL 226566

CLIENT SERVICE

T: +61 2 8524 9900

F: +61 2 8524 9901

E: clientservice@pengana.com



PENGANA.COM

Pengana Capital Limited (ABN 30 103 800 568, AFSL 226566) ("Pengana") is the issuer of units in the Pengana High Conviction Equities Fund (ARSN 602 546 332) (the "Fund"). A Product Disclosure Statement (PDS) and Target Market Determination are available and can be obtained from our distribution team or website. A person should obtain a copy of the product disclosure statement and should consider the product disclosure statement carefully before deciding whether to acquire, or to continue to hold, or making any other decision in respect of, the units in the Fund. This report was prepared by Pengana and does not contain any investment recommendation or investment advice. This report has been prepared without taking account of any person's objectives, financial situation or needs. Therefore, before acting on any information contained within this report a person should consider the appropriateness of the information, having regard to their objectives, financial situation and needs. Neither Pengana nor its related entities, directors or officers guarantees the performance of, or the repayment of capital or income invested in the Fund.